DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Tirzepatide
Semaglutide
Mounjaro edges out Ozempic in our scoring, 8.4/10 versus 8.3/10. Mounjaro (Tirzepatide) and Ozempic (Semaglutide) are both GLP-1 receptor agonists; the gap comes from differences in efficacy data, cost, and access. Neither is universally better — the right choice depends on your insurance, diagnosis, and tolerance.
Mounjaro (tirzepatide) and Ozempic (semaglutide) are both weekly injections FDA-approved for type 2 diabetes, but Mounjaro is a dual GIP/GLP-1 agonist while Ozempic targets GLP-1 alone. In the head-to-head SURPASS-2 trial, Mounjaro produced greater A1C reduction (−2.30% vs −1.86%) and roughly twice the weight loss.
Boxed warning (class-wide for GLP-1s): risk of thyroid C-cell tumors. Contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
| Attribute | Mounjaro | Ozempic |
|---|---|---|
| Mechanism | Dual GIP/GLP-1 receptor agonist FDA label | GLP-1 receptor agonist FDA label |
| A1C reduction (SURPASS-2, 40 wk) | 2.30 % | 1.86 % |
| Weight loss (SURPASS-2, 40 wk) | 11.2 kg Tirzepatide 15 mg | 5.7 kg Semaglutide 1 mg |
| FDA indication | Type 2 diabetes FDA label (weight loss off-label) | Type 2 diabetes FDA label (weight loss off-label) |
| Retail cash price | $1,025/mo Retail cash (Mounjaro) | $997/mo Retail cash (Ozempic) |
| Manufacturer cash-pay | 549 $/mo LillyDirect (Mounjaro) | 499 $/mo NovoCare (Ozempic) |
| Rx status | Rx only FDA | Rx only FDA |
| Effect | Mounjaro | Ozempic |
|---|---|---|
| Nausea | 18% | 20% |
| Diarrhea | 17% | 9% |
| Vomiting | 9% | 9% |
FDA prescribing-info baselines. Lower is better (green).
Switching between Mounjaro and Ozempic is a change of molecule (tirzepatide ↔ semaglutide), not a dose conversion — a prescriber restarts titration at the new drug’s starting dose and steps up over weeks. Both are FDA-approved for type 2 diabetes; weight loss is off-label for each. People usually switch to Mounjaro for greater A1C and weight reduction, or to Ozempic for a lower cash price or its cardiovascular-outcomes data.
Independently sourced from the cited trials; last verified July 2026. Editorial summary, not medical advice — see our methodology and editorial standards.
Mounjaro scores 8.4/10 vs Ozempic at 8.3/10. Detailed breakdown below.
Tirzepatide for type 2 diabetes
Semaglutide approved for type 2 diabetes
Highest combined score across six axes. Semaglutide approved for type 2 diabetes
| # | Product | Active ingredient | Starting price | True cost · maint. | FDA status | Score | |
|---|---|---|---|---|---|---|---|
| 1 | Mounjaro | Tirzepatide | $1349/mo | $549/mo · 7.5mg+$150 | off-label | Top ·8.4 | View → |
| 2 | Ozempic | Semaglutide | Best ·$997/mo | Best ·$499/mo · 1mg | off-label | 8.3 | View → |
Mounjaro (Tirzepatide) and Ozempic (Semaglutide) both belong to the GLP-1 receptor agonist class, but their molecular structure and dosing differ enough to produce different real-world outcomes. Head-to-head trial data is limited; most comparisons come from cross-trial analysis of pivotal studies (STEP-1, SURMOUNT-1, SELECT, SUSTAIN).
On weight loss, Mounjaro typically shows stronger placebo-adjusted reductions at 68 weeks, with greater proportions of patients reaching ≥15% body-weight loss. For type 2 diabetes patients, A1C reduction tends to track with the drug's underlying glucose-handling mechanism — single-agonist semaglutide compounds (Wegovy, Ozempic, Rybelsus) yield ~1.5% A1C drop, while dual GIP/GLP-1 agonists (Mounjaro, Zepbound) frequently exceed 2.0%.
GI side effects dominate the first 8-12 weeks of GLP-1 therapy regardless of which drug you start on. Nausea (35-45%), diarrhea (15-25%), constipation (15-20%), vomiting (10-15%), and headache (10-15%) are the most reported. Mounjaro and Ozempic share this profile; the difference is usually in titration aggressiveness and individual tolerance, not the drug itself.
More serious but rare adverse events — pancreatitis, gallbladder disease, kidney injury during dehydration, and the boxed warning for medullary thyroid cancer in rodent models — apply to the entire GLP-1 class. If you have a personal or family history of MTC or MEN2, neither Mounjaro nor Ozempic is appropriate. Talk to your prescribing physician about your risk profile before starting either.
Without insurance coverage, both Mounjaro and Ozempic run between $1,000 and $1,400 per month at list price. Coverage decisions hinge on whether your plan treats the drug as a weight-loss medication (often excluded from formulary) or a diabetes medication (typically covered). Medicare Part D specifically excludes weight-loss indications under current rules, so a Wegovy prescription is denied even though Ozempic (same molecule) is covered for T2D — a gap that drives many switching decisions.
Manufacturer savings cards can lower out-of-pocket cost to as little as $25-$650/month for commercially insured patients depending on plan tier. If you're uninsured or your plan rejects coverage, compounded semaglutide and tirzepatide from licensed 503A/503B pharmacies are typically 60-80% cheaper but carry quality-variability and supply-chain risks that brand drugs don't.
Switching from Mounjaro to Ozempic (or vice versa) is generally straightforward but requires a careful titration restart, not a direct dose swap. Your prescriber will typically pause for 1 week, then begin the new drug at its lowest dose regardless of where you were on the original. This minimizes GI side effects from a full-strength reintroduction. Expect 4-12 weeks before reaching the maintenance dose on the new medication.
Reasons people switch include: insurance formulary changes, shortage of the original drug, intolerable side effects, plateauing weight loss, or moving from a single-agonist to a dual-agonist compound. The choice should always go through your prescribing physician — do not self-switch using compounded products without medical supervision.
Mounjaro is our editorial pick in this matchup with an overall score of 8.4/10, edging out Ozempic at 8.3/10. The score reflects a weighted average of clinical efficacy, safety profile, cost transparency, and access — not just trial outcomes. For most patients comparing these two, insurance coverage and pharmacy access will outweigh the scoring differential. Verify both with your prescriber and plan before committing.
Eli Lilly joins TrumpRx with Zepbound + Mounjaro at $549/mo cash. Plus: FDA Q1 enforcement actions, Hims settlement aftermath, and three new compounders we are watching.
Read issue →The 28-month Wegovy shortage ended this week. Compounders now face 60-day wind-down. What this means for the ~1.2M patients on compounded semaglutide — and your prescription path forward.
Read issue →Medicare Part D will cover Wegovy for obesity starting July 1, 2026 — but with strict prior auth. We obtained the draft PA criteria and cross-checked every line against the published rule.
Read issue →